The estimated Net Worth of Sam R Leno is at least $7.04 Million dollars as of 5 March 2024. Mr. Leno owns over 4,090 units of Lantheus Inc stock worth over $6,115,165 and over the last 17 years he sold LNTH stock worth over $727,800. In addition, he makes $199,993 as Independent Director at Lantheus Inc.
Samuel has made over 19 trades of the Lantheus Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he exercised 4,090 units of LNTH stock worth $66,667 on 5 March 2024.
The largest trade he's ever made was exercising 100,000 units of Lantheus Inc stock on 6 June 2011 worth over $10,195,000. On average, Samuel trades about 15,128 units every 160 days since 2008. As of 5 March 2024 he still owns at least 59,982 units of Lantheus Inc stock.
You can see the complete history of Mr. Leno stock trades at the bottom of the page.
Samuel R. Leno serves as Independent Director of the Company. He is a Director and the Chairperson of the Audit Committee and member of the Financing and Strategy Committee, serving on the Board since May 2012. Mr. Leno is a strategic executive with more than 40 years of experience with complex multinational companies. He most recently held the positions of Executive Vice President and Chief Operations Officer at Boston Scientific. He previously served as Executive Vice President, Finance and Information Systems and Chief Financial Officer. He retired from Boston Scientific in December 2011. Prior to joining Boston Scientific, Mr. Leno served as Executive Vice President, Finance and Corporate Services and Chief Financial Officer at Zimmer Holdings, Inc. and Chief Financial Officer positions at Arrow Electronics, Inc., Corporate Express, Inc. and Coram Healthcare. Previously, he held a variety of senior financial positions at Baxter International, Inc. and American Hospital Supply Corporation. He currently serves on the Board of Directors and as Chairman of the Audit Committee of GCM Holding Corp. He was the Chairman of the Board of Directors and of the Audit Committee of Zest Dental Solutions until it was acquired in 2018. He also previously served on the Boards of Directors and the Audit Committees of Omnicare and TomoTherapy, Inc. and served on the Board of Directors of Endotronix, Inc. Mr. Leno served as a Lieutenant in the United States Navy and is a Vietnam veteran. He holds a Bachelor of Science in Accounting from Northern Illinois University and a Master of Business Administration from Roosevelt University. Mr. Leno was chosen as a Director because of his financial expertise and industry background.
As the Independent Director of Lantheus Inc, the total compensation of Samuel Leno at Lantheus Inc is $199,993. There are 10 executives at Lantheus Inc getting paid more, with Mary Heino having the highest compensation of $4,320,910.
Samuel Leno is 74, he's been the Independent Director of Lantheus Inc since 2012. There are 1 older and 25 younger executives at Lantheus Inc. The oldest executive at Lantheus Holdings Inc is James Thrall, 76, who is the Independent Director.
Sam's mailing address filed with the SEC is C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON ROAD, SOUTH BLDG, BEDFORD, MA, 01730.
Over the last 9 years, insiders at Lantheus Inc have traded over $500,725,766 worth of Lantheus Inc stock and bought 8,000 units worth $141,200 . The most active insiders traders include David F Burgstahler, Capital Partners Gp, Llc Av... und Sriram Venkataraman. On average, Lantheus Inc executives and independent directors trade stock every 11 days with the average trade being worth of $15,777,680. The most recent stock trade was executed by James H Thrall on 21 August 2024, trading 1,000 units of LNTH stock currently worth $98,520.
lantheus holdings, inc. (nasdaq: lnth) is the parent company of lantheus medical imaging, inc. (lmi), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. lmi provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. lmi’s key products include the echocardiography contrast agent definity® vial for (perflutren lipid microsphere) injectable suspension; technelite® (technetium tc99m generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and xenon (xenon xe 133 gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. the company is headquartered in north billerica, massachusetts with offices in puerto rico and canada. for more information, visit www.lantheus.com.
Lantheus Inc executives and other stock owners filed with the SEC include: